CZ20012032A3 - Nové způsoby léčby zhoubného bujení - Google Patents

Nové způsoby léčby zhoubného bujení

Info

Publication number
CZ20012032A3
CZ20012032A3 CZ20012032A CZ20012032A CZ20012032A3 CZ 20012032 A3 CZ20012032 A3 CZ 20012032A3 CZ 20012032 A CZ20012032 A CZ 20012032A CZ 20012032 A CZ20012032 A CZ 20012032A CZ 20012032 A3 CZ20012032 A3 CZ 20012032A3
Authority
CZ
Czechia
Prior art keywords
treatment methods
novel treatment
malignant proliferation
derivatives
cells
Prior art date
Application number
CZ20012032A
Other languages
English (en)
Other versions
CZ300499B6 (cs
Inventor
Angus George Dalgleish
Peter Michael Smith
Andrew Derek Sutton
Anthony Ian Walker
Original Assignee
Onyvax Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Onyvax Limited filed Critical Onyvax Limited
Publication of CZ20012032A3 publication Critical patent/CZ20012032A3/cs
Publication of CZ300499B6 publication Critical patent/CZ300499B6/cs

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/884—Vaccine for a specifically defined cancer prostate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CZ20012032A 1998-12-10 1999-12-09 Použití bunecných linií lidské prostaty k lécbe zhoubného bujení prostaty CZ300499B6 (cs)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9827104.2A GB9827104D0 (en) 1998-12-10 1998-12-10 New cancer treatments

Publications (2)

Publication Number Publication Date
CZ20012032A3 true CZ20012032A3 (cs) 2001-10-17
CZ300499B6 CZ300499B6 (cs) 2009-06-03

Family

ID=10843926

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ20012032A CZ300499B6 (cs) 1998-12-10 1999-12-09 Použití bunecných linií lidské prostaty k lécbe zhoubného bujení prostaty

Country Status (19)

Country Link
US (3) US6972128B1 (cs)
EP (1) EP1137422B1 (cs)
JP (2) JP4949554B2 (cs)
KR (1) KR20010090874A (cs)
AT (1) ATE304365T1 (cs)
AU (1) AU763485B2 (cs)
CA (1) CA2354045C (cs)
CZ (1) CZ300499B6 (cs)
DE (1) DE69927286T2 (cs)
ES (1) ES2249046T3 (cs)
GB (1) GB9827104D0 (cs)
HU (1) HUP0104568A3 (cs)
IL (2) IL143296A0 (cs)
MX (1) MXPA01005816A (cs)
NO (1) NO327044B1 (cs)
NZ (1) NZ512004A (cs)
PL (1) PL201016B1 (cs)
WO (1) WO2000033869A2 (cs)
ZA (1) ZA200104164B (cs)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9827104D0 (en) * 1998-12-10 1999-02-03 Onyvax Ltd New cancer treatments
GB9827103D0 (en) * 1998-12-10 1999-02-03 Onyvax Ltd New cancer treatments
AU4935700A (en) * 1999-05-21 2000-12-12 Onyvax Limited New vaccine formulations-3
ATE507285T1 (de) * 2000-04-01 2011-05-15 Onyvax Ltd Prostata zellinien und deren verwendung
US6667479B2 (en) * 2001-06-01 2003-12-23 Raytheon Company Advanced high speed, multi-level uncooled bolometer and method for fabricating same
US20050019336A1 (en) 2003-07-23 2005-01-27 Dalgleish Angus George Human prostate cell lines in cancer treatment
CA2536669A1 (en) * 2003-08-26 2005-03-17 Becton, Dickinson And Company Methods for intradermal delivery of therapeutics agents
CN105664147A (zh) * 2007-02-07 2016-06-15 日本电气株式会社 用于癌症的治疗剂
WO2009066462A1 (ja) * 2007-11-20 2009-05-28 Nec Corporation 細胞傷害性ｔ細胞の誘導方法、細胞傷害性ｔ細胞の誘導剤、およびそれを用いた医薬組成物およびワクチン
AU2009200767A1 (en) * 2008-03-10 2009-09-24 Aristocrat Technologies Australia Pty Limited A gaming system and a method of gaming
WO2010057197A1 (en) 2008-11-17 2010-05-20 The Regents Of The University Of Michigan Cancer vaccine compositions and methods of using the same

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993006867A1 (en) * 1991-10-04 1993-04-15 Whitehead Institute For Biomedical Research The regulation of systemic immune responses utilizing cytokines and antigens
JPH05246889A (ja) * 1992-03-05 1993-09-24 Seitai Chiyousetsu Kenkyusho:Kk 制癌方法および制癌剤
WO1995029704A1 (en) * 1994-04-28 1995-11-09 Scott Freeman Cell lines obtained by in vivo migration and by fusion with autoimmune cells
KR19980703072A (ko) * 1995-03-17 1998-09-05 스티븐슨 린다 에스 종양의 치료방법
US5788963A (en) * 1995-07-31 1998-08-04 Pacific Northwest Cancer Foundation Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
ATE237338T1 (de) * 1995-12-28 2003-05-15 Univ Johns Hopkins Med Allogene parakrine cytokine tumor impfstoffe
JP2000506379A (ja) * 1996-02-02 2000-05-30 アメリカ合衆国 ヒト前立腺上皮不死細胞の細胞株およびクローンおよびそれらの研究および前立腺癌治療に対する応用
GB9620350D0 (en) * 1996-09-30 1996-11-13 Maudsley David J Cancer vaccine
US6207805B1 (en) * 1997-07-18 2001-03-27 University Of Iowa Research Foundation Prostate cell surface antigen-specific antibodies
GB9827104D0 (en) * 1998-12-10 1999-02-03 Onyvax Ltd New cancer treatments

Also Published As

Publication number Publication date
NO327044B1 (no) 2009-04-06
JP2002531520A (ja) 2002-09-24
KR20010090874A (ko) 2001-10-19
IL143296A (en) 2006-06-11
CA2354045A1 (en) 2000-06-15
EP1137422B1 (en) 2005-09-14
EP1137422A2 (en) 2001-10-04
WO2000033869A3 (en) 2000-10-12
JP4949554B2 (ja) 2012-06-13
ES2249046T3 (es) 2006-03-16
US20120164099A1 (en) 2012-06-28
US8034360B2 (en) 2011-10-11
ZA200104164B (en) 2002-01-24
GB9827104D0 (en) 1999-02-03
NO20012634L (no) 2001-08-08
JP2012021028A (ja) 2012-02-02
CA2354045C (en) 2012-02-21
PL201016B1 (pl) 2009-02-27
NZ512004A (en) 2003-08-29
PL348828A1 (en) 2002-06-17
AU763485B2 (en) 2003-07-24
US20050249756A1 (en) 2005-11-10
NO20012634D0 (no) 2001-05-29
DE69927286T2 (de) 2006-06-29
WO2000033869A2 (en) 2000-06-15
ATE304365T1 (de) 2005-09-15
AU1668300A (en) 2000-06-26
HUP0104568A3 (en) 2004-05-28
MXPA01005816A (es) 2002-03-27
IL143296A0 (en) 2002-04-21
DE69927286D1 (de) 2005-10-20
US6972128B1 (en) 2005-12-06
CZ300499B6 (cs) 2009-06-03
HUP0104568A2 (hu) 2002-03-28

Similar Documents

Publication Publication Date Title
GEP20094798B (en) (s,s)-reboxetine for treating chronic pain
ES2191152T3 (es) Terapia combinada para el tratamiento de psicosis.
MXPA04002593A (es) Composiciones y metodos para el diagnostico y tratamiento de tumor.
MXPA03011985A (es) Composiciones y metodos para el diagnostico y tratamiento de tumores.
NO20021830L (no) Sammensetninger egnet til å forhindre og behandle forkjölelse og influensaliknende symptomer samt fremgangsmåter vedfremstilling derav
MY136095A (en) Use of human anti-ctla-4 antibodies for treatment of cancer
EP1381280A4 (en) VIRAL VECTORS AND USE THEREOF IN THERAPEUTIC METHODS
CZ20012032A3 (cs) Nové způsoby léčby zhoubného bujení
MXPA05005107A (es) Composiciones y metodos para el diagnostico y tratamiento de tumores.
YU3902A (sh) Imidazoimidazoli i triazoli kao anti-inflamatorna sredstva
NZ285159A (en) Treatment of benign prostatic hyperplasia, endometriosis, prostatic carcinoma and obesity by administration of droloxifene
WO2004112825A3 (en) Combinations of tumor-associated antigens for the treatment of various types of cancers
PT967987E (pt) Composicoes para o tratamento de tumores contendo extractos de cartilagem de tubarao e agentes antineoplasicos
WO1992002240A3 (en) Novel methods and compositions for treatment of angiogenic diseases
DE60040213D1 (de) Tumorimpfstoff
DE69938192D1 (en) Imidazonaphthyridine
EP1546182A4 (en) COMPOSITIONS AND METHOD FOR DIAGNOSING AND TREATING TUMORS
EP0951475A4 (en) Vaccine against metastatic colorectal cancer.
AU3439799A (en) Immunization against and treatment for infection by (h.pylori)
NZ512850A (en) Treatment of papillomavirus infections
IL143279A0 (en) Novel therapeutic application of low molecular weight heparin
IL148336A0 (en) Medicaments that contain xenogenic oligo-or/and polyribonucleotides
ES2169986A1 (es) Uso de cdp-colina para el tratamiento profilactico de la isquemia cerebral.
ZA200203985B (en) Therapies for tissue damage resulting from ischemia.
ES2183734A1 (es) Derivados de 4-4'-bipiridil-2-2'-bisoxazoles y 4-4'-bipiridil-2-2'-bistiazoles como agentes antineoplasicos.

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of fee

Effective date: 19991209